Class / Patent application number | Description | Number of patent applications / Date published |
435700500 | Involving avidin-biotin binding | 51 |
20080213801 | Monomeric streptavidin muteins - The invention includes a streptavidin mutein having at least one mutation chosen to cause one or more of steric hindrance, charge repulsion, or improvement of solubility by changing interfacial hydrophobic residues to less hydrophobic or hydrophilic residues. The mutein may exist in monomeric form even in the presence of biotin, and reversibly binds to biotin. The invention also includes polynucleotides encoding such muteins, expression systems and host cells for producing such muteins. The invention also includes a method of capturing biotinylated molecules using the muteins of the invention. | 09-04-2008 |
20090275052 | ADJUSTABLE MOLECULAR MOTOR MICROPOWER BIOSENSOR AND ITS APPLICATION - A regulable molecular motor micropower biosensor comprises: a rotary motor, an optical energy conversion device, a signal molecular output device, a power resource system, a protective layer, a supporting material, and a bilayer lipid membrane fixing material. The molecular motor micropower biosensor is used for detecting biological macromolecules, viral molecules, etc. | 11-05-2009 |
20100086945 | DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. | 04-08-2010 |
20100099120 | Method for staining substances having a phosphate group - It is intended to provide a method by which a substance having a phosphate group can be easily detected from a biological sample or the like, a method by which a phosphorylated amino acid residue is easily identified and a compound which can be used in the methods because of having a high coordinate bond forming capacity with a substance having a phosphate group. A metal complex compound represented by the general formula (I): {wherein M represents a metal atom which can be a divalent cation, Rs may be the same or different from one another and represent a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, an acyl group, an alkoxycarbonyl group, an acylalkyl group, an alkoxycarbonylalkyl group, a carboxyalkyl group, a carbamoylalkyl group, a cyanoalkyl group, a hydroxyalkyl group, an aminoalkyl group or a haloalkyl group (here, the carbon number of alkyl moiety of these groups is 1 to 16), a carboxyl group, a carbamoyl group, a cyano group, a hydroxyl group, an amino group or a halogen group, X represents a ligand and Y represents a labeling group} can easily identify a substance having a phosphate group because of having a high coordinate bond forming capacity with a substance having a phosphate group and having the labeling group. | 04-22-2010 |
20100105077 | Means for Detection and Purification of CD8+ T Lymphocyte Populations Specific to Peptides Presented in the Context of HLA - The invention concerns multimers developed from recombinant proteins analogues of MHC class I. | 04-29-2010 |
20100143941 | DEVICES AND METHODS FOR DETECTING ANALYTES - This invention provides devices and methods for detecting an analyte suspected to be present in a sample. The subject devices and methods are particularly useful for performing immunoassays on a variety of analyte, especially those present in a bodily fluid. | 06-10-2010 |
20100178657 | MOLECULAR ASSEMBLY ON A SUBSTRATE - The present invention relates to a molecular assembly on a substrate usable for studying and/or performing biological interactions and/or reactions The invention further relates to an in vitro method to provide a substrate with a heparin coating presenting biotinylated biomolecules comprising linking avidin to a surface capable of binding avidin. A heparin conjugate is then linked to the avidin treated surface to form a layer of heparin thereon. Finally, a biotinylated biological probe or biomolecule is linked to the avidin through the layer of heparin thereby forming an essentially biologically inert surface with biotinylated probes extending out from the surface. | 07-15-2010 |
20100240069 | Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity - The present invention relates to a high throughput assay for determining HIF 1α prolyl hydroxylation. | 09-23-2010 |
20100285503 | FRET-BASED BINDING ASSAY - The present invention provides for an assay that identifies kinase inhibitors by employing fluorescence resonance energy transfer in a competition binding approach. | 11-11-2010 |
20110124010 | DIAGNOSTIC METHOD - A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein. | 05-26-2011 |
20110136139 | METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES - Semiconductor nanoparticle complexes comprising semiconductor nanoparticles in association with cationic polymers are described. Also described are methods for enhancing the transport of semiconductor nanoparticles across biological membranes to provide encoded cells. The methods are particularly useful in multiplex settings where a plurality of encoded cells are to be assayed. Kits comprising reagents for performing such methods are also provided. | 06-09-2011 |
20110275094 | PHOSPHORYLATED FMS-RELATED TYROSINE KINASE 3 BIOMARKER ASSAY - Provided herein are methods for detecting the presence of human pFLT3 in a sample. An exemplary assay provided herein is an ELISA method (e.g., sandwich ELISA). Also provided herein are methods for detecting FLT3 phosphorylation in a sample, diagnosing a patient having a FLT3-activating mutation, identifying a compound that activates or is otherwise and agonist of human FLT3 phosphorylation, identifying a compound that inhibits or is otherwise an antagonist of human FLT3 phosphorylation, determining the efficacy of a compound for increasing, decreasing or otherwise modulating human FLT3 phosphorylation in a patient. Further provided are kits for carrying out the said methods. Such kits comprise at least a total FLT3 antibody optionally immobilized on a solid support and a labeled pFLT3 antibody. | 11-10-2011 |
20110306061 | INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) ACTIVITY FOR REGULATING NEURAL GROWTH AND REGENERATION - The present invention relates generally to products, compositions and methods useful for promoting neural repair and regeneration. The products and compositions of this invention include myelin-associated glycoprotein (MAG) derivatives that are inhibitors of endogenous MAG (e.g., mutant MAG proteins) and Nogo Receptor (NgR) binding inhibitors that are peptides derived from MAG, Nogo and OMgp that can bind to NgR and block NgR signaling. Peptides that can bind and activate NgR signaling are also provided. Inhibitory MAG derivatives and NgR binding inhibitors are useful for blocking the inhibition of neural regeneration mediated by proteins such as MAG, Nogo and/or OMgp in the nervous system. These inhibitors are also useful for treating neural degeneration associated with injuries, disorders or diseases. | 12-15-2011 |
20110311989 | ANTIBODY TO N-TERMINAL REGION OF HEMOGLOBIN BETA-CHAIN - Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified. | 12-22-2011 |
20120003666 | METHOD OF DETECTING TARGET SUBSTANCE - Provided is a method of measuring a being state of a target substance at unknown concentration contained in a sample. The method includes identifying a kind of a target substance when one kind of target substance is contained in a sample and determining a concentration ratio when plural kinds of target substances are contained in the sample: by obtaining, with respect to each of plural kinds of known substances having the same recognition site, a relationship between Parameter A of the known substance and Parameter B of the known substance; and measuring Parameter A of the target substance contained in the sample and Parameter B of the target substance contained in the sample, wherein Parameter A of X is a value derived from a number of molecules of X and Parameter B of X is a value derived from the number and a molecular weight of X. | 01-05-2012 |
20120009595 | BINDING OF AGGREGATED FORMS OF PROTEINS - Aggregating proteins such as IgG, are bound selectively in the presence of the non-aggregated protein using a polyionic binding agent such as dextran sulphate or pentosan (anionic), or polyamine compounds such as pDADMAC (cationic) under selective binding conditions including the use of n-lauroylsarcosine at mildly alkaline pH, and may then be assayed. | 01-12-2012 |
20120021435 | DETECTION OF LIVING, CIRCULATING, OR DISSEMINATED CELLS OR CELL CONSTITUENTS IN BLOOD OR BONE MARROW FOLLOWING FILTRATION OF BLOOD - A method is disclosed for detecting circulating cells in a body fluid sample. In at least one embodiment, the method includes: filtering the body fluid sample through a porous membrane; transferring the porous membrane with the cells located thereon as filter residue to a cell culture vessel, wherein one surface of the cell culture vessel is coated with a first antibody which is directed to a first cell-specific marker; incubating the porous membrane in the cell culture vessel with a cell culture medium, wherein cell-specific markers released by any cells present are bound by the first antibody to produce a bound first cell-specific marker on the surface coated with the first antibody; removing the porous membrane with the cells located thereon as filter residue from the cell culture vessel; detecting the bound first cell-specific marker on the surface coated with the first antibody. | 01-26-2012 |
20120064543 | METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE - The present invention provides a method for detecting a substance in a biological sample, a carrier for using in the method, and a kit. The method of the present invention according to an embodiment includes:
| 03-15-2012 |
20120094308 | KIT AND METHOD FOR THE PREMORTEM IN VITRO DETECTION OF ALZHEIMER'S DISEASE - Kit and method for the pre mortem in vitro detection of Alzheimer's disease The invention relates to a detection kit for Alzheimer's disease based on the vitro identification of the presence of biomarkers in the remains normally discarded after crystalline lens surgery. The kit can be used for the pre mortem detection of the disease, even before the appearance of clinical symptoms. Among the available biomarkers, the biomarker of choice is beta-amyloid peptide, for which several methods of sample processing and labelling for the presence of the biomarker may be used. Embodied in the invention is also the use of the crystalline lens remains discarded during surgery, often cataract surgery, to prepare a method for the in vitro pre mortem detection of Alzheimer's disease. | 04-19-2012 |
20120107834 | ENCAPSULATED REAGENTS AND METHODS OF USE - The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens. | 05-03-2012 |
20120107835 | METHOD FOR DETECTING BETA-AMYLOID USING AMINO ACID DIMERS - A method for detecting β-amyloid using an amino acid dimer instead of a secondary antibody binding to the β-amyloid primary antibody in an immunoassay based on an antigen-antibody reaction, and a kit for detecting β-amyloid including the dimer. The method is advantageous in that the dimer has good properties in stability, availability, and storage compared to antibodies and that it can detect various β-amyloids by using one kind of antibody, and thus may be effectively used in early diagnosis and research of Alzheimer's disease. | 05-03-2012 |
20120122118 | Monclonal antibodies, hybridomas and methods for use - The present invention provides monoclonal antibodies to TM9SF-proteins and hybridoma cell lines that produce the monoclonal antibodies to TM9SF4. This invention also provides a method for determining the level of TM9SF4-protein in biological fluid samples, tissue samples and in microvesicles such as exosomes, comprising kit for determining the level of TM9SF4 protein in human exosomes and other microvesicles, in tissue samples, and in biological fluids. | 05-17-2012 |
20120142023 | PROTEINS AND METHOD FOR DETECTION OF LYME DISEASE - Recombinant | 06-07-2012 |
20120164660 | METHOD FOR USING A DIAGNOSTIC AGENT WHICH INCLUDES A CALCIUM BINDING PROTEIN ASSAY REAGENT AND ASSAY METHOD FOR CALCIUM BINDING PROTEIN - A bovine- or human-derived calcium-binding protein with a prescribed amino acid sequence, a method for its production, and antibodies against the protein and uses thereof. | 06-28-2012 |
20120164661 | METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION - The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays. | 06-28-2012 |
20120171697 | Method of Determining Inhibitors of Coagulation - A homogeneous method of determining inhibitors of proteolytically active coagulation factors (anticoagulants) in a sample, in particular direct thrombin and factor Xa inhibitors, and also a test kit to be used in such a method. Use is made of ligands which bind to the proteolytically active coagulation factor but are not cleaved by the latter and compete with the anticoagulant to be determined. | 07-05-2012 |
20130065249 | SIGNAL AMPLIFICATION FOR IMMUNOASSAYS BY USE OF AVIDIN-BIOTIN LINKAGES - In sandwich-type immunoassays that capture a protein analyte between a capture antibody, typically bound to a solid phase, and a detection antibody that is coupled to a reporter group, the number of reporter groups associated with each molecule of analyte is increased by a variety of methods that utilize avidin-biotin-type binding in conjunction with such features as immunological binding to the reporter group on the detection antibody or multiple biotin-avidin-type binding sites. | 03-14-2013 |
20130115621 | HIGHLY SENSITIVE IMMUNOASSAYS AND ANTIBODIES FOR DETECTION OF BLOOD FACTOR VIII - Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia. | 05-09-2013 |
20130130278 | DETECTION OF RISK FOR PREGNANCY-RELATED MEDICAL CONDITIONS - Generally, there is provided a method of determining risk of determining intrauterine growth restriction (IUGR)/fetal growth restriction (FGR). The method comprises obtaining a sample from a pregnant woman, taking a measurement indicative of IGFBP-4 level in the sample, and determining that increased of IUGR/FGR exists if the IGFBP-4 level is elevated. The sample may be taken during the first trimester of pregnancy, and may comprise maternal serum. The measurement may be one of IGFBP-4 protein which may be made using an immunoassay, such as a Western blot or an enzyme-linked immunosorbent assay (ELISA). | 05-23-2013 |
20130137117 | METHOD FOR PREPARING PROTEIN IMPRINTED POLYMERS AND USE THEREOF - Methods for preparation of molecularly imprinted polymers and their use for detection of proteins and/or polypeptides in a sample are disclosed. The methods of preparation are based on selecting from available data bases an amino acid sequence of a protein/polypeptide target molecule; cleaving the sequence in-silico with at least one cleaving agent, producing fragments with known composition; selecting at least one such fragment comprising a unique epitope; preparing a synthetic peptide representing the unique epitope; and preparing a molecularly imprinted polymer comprising specific binding sites for the synthetic peptide. For detection of the target protein in a sample, the same cleaving agent used for the in-silico cleavage is used to cleave the target protein to form the specific peptide fragments to which the MIP is specific. | 05-30-2013 |
20130143233 | FUSION PROTEIN HAVING LUMINESCENCE ACTIVITY - The fusion protein comprising (1) a first region comprising the amino acid sequence of SEQ ID NO: 18 and (2) a second region comprising an amino acid sequence for a polypeptide containing at least one cysteine residue for binding to other useful compound via the thiol group can be modified by chemical modification, and thus has a high catalytic ability for a luminescence activity and is highly available for general purposes. | 06-06-2013 |
20130189707 | METHOD OF DETERMINATION OF AUTOANTIBODY LEVEL BY MEANS OF ENZYME IMMUNOASSAY - The method for quantitative determination of the level of natural autoantibodies in human biological fluids, when as a solid phase of physical sorption is used the solid phase of physical sorption, coated with streptavidin, and the solid phase of physical sorption is treated with preliminary biotinylated antigen and blocking agent for closing the sites of nonspecific binding at the solid phase of physical sorption, for which purpose are used proteins, biotinylated according to standard procedure. As the conjugate-containing solution are used enzyme-labeled monoclonal and polyclonal antibodies, which react with one or all isotypes of human immunoglobulins. In addition, the tested biological fluid is preliminary diluted in a buffer, containing proteins which are used for closing the sites of nonspecific binding at solid phase of physical sorption, and also substances protecting natural autoantibodies from destruction during heat treatment, and subjected to heat treatment. For each tested specimen of biological fluid, a control solid phase of physical sorption is used, and the number of natural autoantibodies is determined with the use of a calibration curve which is plotted using monoclonal or polyclonal antibodies to antigen. | 07-25-2013 |
20130203075 | METHOD FOR DETECTING ANTI-DRUG ANTIBODIES - The present inventions relates to the monitoring or assaying of anti-bio-agent antibodies, such as anti-drug antibodies (ADA) in patients who may have developed an antibody response in treatments with immunoglobulin bio-agents. | 08-08-2013 |
20130309691 | USE OF HEAT-RESISTANT BIOTIN-BINDING PROTEIN, AND SOLID SUPPORT HAVING THE PROTEIN ATTACHED THERETO - The present invention relates to a solid support having a heat-resistant biotin-binding protein attached thereto. The present invention also relates to the use of the solid support of the present invention having a heat-resistant biotin-binding protein attached thereto. The present invention further relates to technical fields such as purification, concentration, detection and/or capture of a biotin-linked substance by means of a heat-resistant biotin-binding protein. Such a biotin-binding protein used in the solid support of the present invention is heat-resistant and is therefore useful for use in assay systems involving exposure to a temperature of 70° C. or more. | 11-21-2013 |
20140273009 | COMPOSITIONS AND METHODS FOR PERFORMING ASSAYS - The disclosure relates to compositions for use in assays, the compositions comprising at least one latent fluorophore including at least one enzyme-reactive quenching group and a conjugative group; and a support connectable to the latent fluorophore by the conjugative group. The disclosure further relates to methods of measuring the presence and/or concentration of an analyte, as well as methods of measuring the relative activity of at least two enzymes. | 09-18-2014 |
20140273010 | ACID-CLEAVABLE AND CLICKABLE AFFINITY CAPTURE PROBE - The present disclosure relates to biological probes useful for detecting the presence of a target molecule. The biological probes are capable of forming complexes with the target molecule that are stable to reduction, oxidation and hydrolysis. | 09-18-2014 |
20150064717 | METHOD FOR STAINING TISSUE - Provided is a method for staining a tissue enabling highly precise staining, by which the expression amount and/or the location of a biological substance in a tissue sample can be detected with a high quantitativity together with detailed information that can be obtained by bright field observation. | 03-05-2015 |
20150064718 | ORGANIC/INORGANIC MAGNETIC COMPOSITE, METHODS OF MAKING AND USE THEREOF - An organic/inorganic composite is provided. The organic/inorganic composite materials are sufficiently hard and brittle to be ground to form particles suitable for biological or chemical separation applications. The organic/inorganic composite materials can be magnetic or magnetically susceptible and can have functional reactive groups to allow attachment of biomolecules. Methods of making and using the organic/inorganic composites are also provided. | 03-05-2015 |
20150118692 | ACOUSTICALLY RESPONSIVE PARTICLES - Acoustically responsive particles and methods are provided for their use. Methods are provided for making and using tunable, monodisperse acoustically responsive particles and negative contrast acoustic particles, wherein the particles can contain a functional group available for covalent modification. | 04-30-2015 |
20150293084 | BIOSENSOR COMPRISING METAL NANOPARTICLES - The present invention discloses a biosensor for visual detection of an analyte, based on the light to heat conversion properties of metal nanoparticles: the analyte is visually detected by the color change in the support areas (where the analyte is present), produced as a result of the heat generated by the metal nanoparticles where they are irradiated with an external light source. Use of said biosensor in a method for the detection of analytes is also claimed. | 10-15-2015 |
20150323543 | ANTI-HUMAN IgG1 ANTIBODY - Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays. | 11-12-2015 |
20150355170 | COMPOSITIONS, SYSTEMS AND METHODS THAT DETECT AND/OR REMOVE CROSS-REACTIVE ANTIBODIES FROM A BIOLOGICAL SAMPLE - The present invention generally relates to compositions, systems and methods that detect and/or remove cross-reactive antibodies from a biological sample. In many cases, the cross-reactive antibodies are human anti-animal antibodies. In certain cases, the cross-reactive antibodies are human anti-mouse antibodies. | 12-10-2015 |
20160054208 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING METHOD - An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do not need to be physically removed from one apparatus to another. The reaction conditions for treating a slide can preferably be controlled independently, including the individualized application of reagents to each slide and the individualized treatment of each slide. | 02-25-2016 |
20160054210 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING METHOD - An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do not need to be physically removed from one apparatus to another. The reaction conditions for treating a slide can preferably be controlled independently, including the individualized application of reagents to each slide and the individualized treatment of each slide. | 02-25-2016 |
20160061844 | PIIINP Neo-epitope Assay - Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognise or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody. | 03-03-2016 |
20160067674 | LIGANDS AND METHODS FOR ISOLATING OR REMOVING PROTEINS - The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation. This significantly improves the protein yield and provides a highly effective isolation of blood plasma protein constituents such as IgG, albumin, factor V and factor VIII in a simple, cheap and time-efficient process. | 03-10-2016 |
20160077100 | Specific Detection of Rat Antibodies in Mouse Serum - One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of
| 03-17-2016 |
20160123966 | CYCLIC-DI-AMP SPECIFIC DETECTION - The present disclosure provides a simple yet fast, cost effective, reliable method for the detection and quantification of cyclic-di-adenosine monophosphate (c-di-AMP) by measuring c-di-AMP binding to a c-di-AMP-binding protein (CabP). A sample is contacted with CabP in the presence of biotin-labeled c-di-AMP. Once binding has reached equilibrium, unbound c-di-AMP is removed and the CabP-bound c-di-AMP is contacted with an enzyme-conjugated biotin-binding protein and a chromogenic substrate to generate a detectable signal. The signal generated correlates to the amount of unlabeled c-di-AMP in the sample. | 05-05-2016 |
20160123993 | Collagen Type X Alpha-1 Assay - An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting said biological sample with said antibody, and determining the amount of binding of said antibody. | 05-05-2016 |
20160161473 | BIOTIN CONJUGATES OF ANALYTES CONTAINING AMINO, HYDROXYL, OR THIOL FUNCTIONAL GROUPS FOR USE IN IMMUNODIAGNOSTIC ASSAYS - The present disclosure provides a compound having Formula I: | 06-09-2016 |
20160195556 | 25-OH VITAMIN D DERIVATIVES FOR DETERMINING VITAMIN D METABOLITES | 07-07-2016 |